2-Methyl-1-quinolin-4-yl-propan-1-one | 83629-97-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-Methyl-1-quinolin-4-yl-propan-1-one
• 英文别名: 2-Methyl-1-(4-quinolinyl)-1-propanone；2-methyl-1-quinolin-4-ylpropan-1-one
• CAS: 83629-97-4
• 化学式: C₁₃H₁₃NO
• 分子量: 199.252
• InChiKey: FGKRTKJQKNLHLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-trimethylstannyl-quinoline 、 异丁酰氯 在 palladium dichloride 作用下， 以 苯 为溶剂， 反应 96.0h， 以28.5%的产率得到2-Methyl-1-quinolin-4-yl-propan-1-one
  参考文献：
  名称：

  Yamamoto, Yutaka; Yanagi, Akihiko, Chemical and pharmaceutical bulletin, 1982, vol. 30, # 6, p. 2003 - 2010

  摘要：

  DOI：

文献信息

• Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
  申请人：Balog Aaron James

  公开号：US20070088029A1

  公开（公告）日：2007-04-19

  Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.

  三环十一烷化合物，以及在治疗核激素受体相关疾病如癌症和免疫紊乱中使用这些化合物的方法，以及含有这些化合物的药物组合物被披露。
• [EN] AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS<br/>[FR] MODULATEURS DE LXR À BASE D'AMINE OU DE (THIO) AMIDE
  申请人：PHENEX FXR GMBH

  公开号：WO2019016269A1

  公开（公告）日：2019-01-24

  The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXRα and/or LXRβ) and act preferably as inverse agonists of LXR.

  本发明涉及公式（I）的衍生物，其结合到肝X受体（LXRα和/或LXRβ），并且作为LXR的拮抗剂。
• MALT1 inhibitors and uses thereof
  申请人：Cornell University

  公开号：US10711036B2

  公开（公告）日：2020-07-14

  Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).

  本文提供的式(I)化合物及其药物组合物可用作 MALT1 抑制剂。还提供了通过施用式（I）化合物治疗增殖性疾病（如癌症（如非霍奇金淋巴瘤、弥漫大 B 细胞淋巴瘤、MALT 淋巴瘤）、良性肿瘤、与血管生成相关的疾病、自身免疫性疾病、炎症性疾病、自身炎症性疾病）。
• YAMAMOTO, YUTAKA;YANAGI, AKIHIKO, CHEM. AND PHARM. BULL., 1982, 30, N 6, 2003-2010
  作者：YAMAMOTO, YUTAKA、YANAGI, AKIHIKO

  DOI：——

  日期：——
• OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING
  申请人：Suzuki Hideyuki

  公开号：US20100256355A1

  公开（公告）日：2010-10-07

  The present invention provides a novel oxazolidinone derivative of the formula (I): wherein Ring A is (A-1) a 7-membered monocyclic heterocycle containing three N atoms; (A-2) a 7-membered monocyclic heterocycle containing two N atoms and one O atom; or (A-3) a 7-membered monocyclic heterocycle containing two N atoms and one S atom, SO or SO 2 , wherein said monocyclic heterocycle is optionally substituted, optionally unsaturated and optionally fused with another ring; X 1 is a single bond, or a heteroatom-containing group selected from the group consisting of —O—, —S—, —NR 2 —, —CO—, —CS—, —CONR 3 —, —NR 4 CO—, —SO 2 NR 5 —, and —NR 6 SO 2 —, wherein R 2 , R 3 , R 4 , R 5 and R 6 are independently hydrogen or lower alkyl, or lower alkylene or lower alkenylene each optionally interrupted by said heteroatom-containing group; Ring B is optionally substituted carbocycle or optionally substituted heterocycle; and R 1 is hydrogen, or an organic residue which is able to bind to the 5 -position of the oxazolidinone ring in oxazolidinone antimicrobial agents, pharmaceutically acceptable salts and solvates thereof which are useful as an antibacterial agent.